Why there needs to be open data for ultra-rare and rare disease drug discovery
MGH Research in IPF: Identifying New Targets for Effective Drug Therapies Andrew M. Tager, M.D. Interstitial Lung Disease Program Pulmonary and Critical.
Four Points: Fatigue George E. Taffet, M.D. Baylor College of Medicine The Methodist Hospital Houston, Texas.
David Shabtai
A8-023287 Tamas Nagy, DVM, PhD Department of Pathology College of Veterinary Medicine University of Georgia Presented at SEVPAC 2008 – Permission granted.
Why Open Source Drug Discovery Needs a “Champion” Sean Ekins, Ph.D., D.Sc. Collaborations In Chemistry, Fuquay Varina, NC.
Knockout Mouse Project (KOMP) and Knockout Mouse Production and Phenotyping (KOMP 2 ) Mouse 101 Oct 19, 2015.
Why Open Source Drug Discovery Needs a “Champion”
